发明名称 Differential diagnostic method and kit for infectious and parasitic diseases, using flow cytometry
摘要 The present invention relates to a differential diagnostic method using flow cytometry, performed by means of differential fluorescent marking of biological agents, such as cells and pathogens of interest, with fluorescent substances. The diagnostic method generally consists in performing fluorescent marking of biological agents with gradual concentrations of fluorescent substances, and in analyzing the reactivity profile of IgG1 to the biological agents. The present invention further relates to a diagnostic kit.
申请公布号 US9588116(B2) 申请公布日期 2017.03.07
申请号 US201314385420 申请日期 2013.03.12
申请人 Fundacao Oswaldo Cruz 发明人 Martins-Filho Olindo Assis;de Carvalho Andrea Teixeira;Rocha Roberta Dias Rodrigues;Andrade Marileia Chaves;Avelar Danielle Marquete Vitelli;Geiger Stefan Michael;Nunes Fernanda Freire Campos;Araujo Marcio Sobreira Silva;Proietti Anna Barbara de Freitas Carneiro;Oliveira Claudia Di Lorenzo;Sabino Ester Cerdeira;Lemos Elenice Moreira
分类号 G01N33/569;G01N21/64 主分类号 G01N33/569
代理机构 Caesar Rivise, PC 代理人 Caesar Rivise, PC
主权项 1. A method for differential diagnosis of diseases associated with infection of a host by trypanosomatids, said diseases including Chagas' disease and Cutaneous Leishmaniasis and Visceral Leishmaniasis, said method comprising the following steps: (a) differential labeling of target trypanosomatides with a first fluorescent substance to provide differentially labeled trypanosomatids, wherein a first type of trypanosomatid is labeled with the first fluorescent substance at a first concentration, a second type of trypanosomatid is labeled with the first fluorescent substance at a second concentration different from the first concentration, and a third type of trypanosomatid is labeled with the first fluorescent substance at a third concentration different from the first and second concentrations; (b) combining and suspending the differentially labeled trypanosomatids of step a) in a buffer solution to provide a suspension; (c) incubation of aliquots of the suspension with serial dilutions of a heat-inactivated human serum sample; (d) incubation of the aliquots from step (c) with human antibody anti-IgG1 conjugated with biotin, in a presence of streptavidin conjugated with a second fluorescent substance to provide a fluorescent labeled anti-IgG1 compound; (e) incubation of the aliquots from step (d) with fixative solution for cytometry to provide flow cytometry samples; (f) obtaining size parameters, granularity and fluorescence signal intensity measurements during analysis of the flow cytometry samples on flow cytometry equipment; (g) multiparametric analysis of an IgG1 reactivity profile of the flow cytometry samples, by determination of a percentage of positive fluorescent trypanosomatids relative to the fluorescence signal of the fluorescent labeled anti-IgG1 compound; and (h) applying a desynchronized algorithm to analytical results obtained in step (g) to determine whether the human serum sample contains antibodies indicative of Chagas' disease, Cutaneous Leishmaniasis or Visceral Leishmaniasis.
地址 Rio de Janeiro BR